Jiangsu Hengrui Pharmaceuticals (SHA:600276) said its Guangdong subsidiary received China's regulatory approval to conduct clinical trials for SHR-1819 Injection,
The drug is indicated for treating atopic dermatitis in children aged six months to five years, according to a Thursday filing with the Shanghai bourse.
Shares of the pharmaceutical company rose 1% in recent trade.